As a proof of principle, we showed in vitro and in vivo that claudin‐binding properties of CPE can be shifted (a) to expand use of CPE to targeting of Cldn1‐expressing thyroid tumors and (b) to potentially reduce CPE side effects by matching the binding properties of CPE to the claudin expression profile of particular carcinoma types. Here, CLDN1 is linked to carcinoma.